A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy

Khaled Nassar; Swaantje Grisanti; Aysegul Tura; Julia Lüke; Matthias Lüke; Mahmoud Soliman; Salvatore Grisanti

doi:10.1016/j.exer.2014.04.006

A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy

Khaled Nassar^*, Swaantje Grisanti, Aysegul Tura, Julia Lüke, Matthias Lüke, Mahmoud Soliman, Salvatore Grisanti

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Augenheilkunde

39 Zitate (Scopus)

Abstract

This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the invitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For invivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation invitro. Invivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation invitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.

Originalsprache	Englisch
Zeitschrift	Experimental Eye Research
Jahrgang	123
Seiten (von - bis)	72-86
Seitenumfang	15
ISSN	0014-4835
DOIs	https://doi.org/10.1016/j.exer.2014.04.006
Publikationsstatus	Veröffentlicht - 01.01.2014

Fördermittel

The work was supported by Ernst and Berta Grimmke-Foundation , Düsseldorf, Germany and Novartis Pharma GmbH , Nürnberg, Germany. We thank Mrs. Christine Oeruen for her technical assistance.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1016/j.exer.2014.04.006

Weitere Links

Link to publication in Scopus

Zitieren

@article{53a202826a7e4ec084f0bb61fd53fdf7,

title = "A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy",

abstract = "This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the invitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For invivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation invitro. Invivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation invitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.",

author = "Khaled Nassar and Swaantje Grisanti and Aysegul Tura and Julia L{\"u}ke and Matthias L{\"u}ke and Mahmoud Soliman and Salvatore Grisanti",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.exer.2014.04.006",

language = "English",

volume = "123",

pages = "72--86",

journal = "Experimental Eye Research",

issn = "0014-4835",

publisher = "Academic Press",

}

TY - JOUR

T1 - A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy

AU - Nassar, Khaled

AU - Grisanti, Swaantje

AU - Tura, Aysegul

AU - Lüke, Julia

AU - Lüke, Matthias

AU - Soliman, Mahmoud

AU - Grisanti, Salvatore

PY - 2014/1/1

Y1 - 2014/1/1

N2 - This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the invitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For invivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation invitro. Invivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation invitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.

AB - This study evaluates the use of the TGF-β receptor 1 inhibitor LY-364947 (LY) to prevent proliferative vitreoretinopathy (PVR). For the invitro experiments Human Tenon's Fibroblasts (HTFs) and retinal pigment epithelial (RPE) cells were treated with different concentrations of LY to determine HTF proliferation and RPE transdifferentiation. For invivo testing 30 rabbits underwent a PVR trauma model. The animals received different concentrations of intravitreally injected LY, with or without vitrectomy. LY treatment reduced HTF proliferation and RPE transdifferentiation invitro. Invivo intravitreal injection of LY prevented PVR development significantly. This positive effect was also present when LY injection was combined with vitrectomy. Intravitreal injection of LY prevented tractional retinal detachment in 14 out of 15 animals. In conclusion, treatment with the TGF-β receptor 1 inhibitor LY reduces HTF proliferation and RPE transdifferentiation invitro and prevents proliferative vitreoretinopathy and subsequent tractional retinal detachment in vivo.

UR - https://www.scopus.com/pages/publications/84899867244

U2 - 10.1016/j.exer.2014.04.006

DO - 10.1016/j.exer.2014.04.006

M3 - Journal articles

C2 - 24742493

AN - SCOPUS:84899867244

SN - 0014-4835

VL - 123

SP - 72

EP - 86

JO - Experimental Eye Research

JF - Experimental Eye Research

ER -

A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy

Abstract

Fördermittel

UN SDGs

Dokumente

Weitere Links

Fingerprint

Zitieren